Please try another search
Centessa Pharmaceuticals plc (Centessa) is a pharmaceutical company. The Company's asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa's clinical-stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The Company's preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The Company's subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.
Name | Age | Since | Title |
---|---|---|---|
Arjun Goyal | 40 | 2021 | Independent Non-Executive Director |
Mathias Hukkelhoven | 69 | 2022 | Independent Non-Executive Director |
Carol Stuckley | 68 | 2021 | Independent Non-Executive Director |
Mary Lynne Hedley | 60 | 2021 | Independent Non-Executive Director |
Francesco de Rubertis | 53 | 2020 | Independent Non-Executive Chairman of the Board |
Samarth Kulkarni | 44 | 2021 | Independent Non-Executive Director |
Brett I. W. Zbar | 50 | 2021 | Independent Non-Executive Director |
Saurabh Saha | 48 | 2021 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review